Regenerative medicine 2.0

Regenerative Medicine

Volumn 2, Issue 1, 2007, Pages 11-18

  Mason, Chris ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOMATION; BURN; CARTILAGE INJURY; CLINICAL PRACTICE; DRUG RESEARCH; EDITORIAL; EMBRYONIC STEM CELL; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEART FAILURE; HUMAN; INTERNET; MEDICAL INFORMATION; MEDICAL INFORMATION SYSTEM; MEDICAL LITERATURE; MEDICAL RESEARCH; NEUROLOGIC DISEASE; ONLINE SYSTEM; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; REGENERATIVE MEDICINE; RESEARCH PRIORITY; SCIENTIST; SOCIAL MARKETING; SOCIAL SUPPORT; SOMATIC CELL; SPINAL CORD INJURY; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE GRAFT; TISSUE REGENERATION; TREATMENT INDICATION;

ASIA; AUSTRALIA; EMBRYONIC STEM CELLS; EUROPE; HUMANS; REGENERATIVE MEDICINE; TISSUE ENGINEERING; UNITED STATES;

EID: 34249701758     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.2.1.11     Document Type: Editorial

References (29)

1. Kemp P: History of regenerative medicine: looking backwards to move forwards. Regenerative Medicine 1(5), 653-669 (2006).
2. Vacanti CA: History of engineering and a glimpse into its future. Tissue Eng. 12(5), 1137-1142 (2006).
3. Lysaght MJ, Hazelhurst A: Tissue engineering: the end of the beginning, Tissue Eng. 10. 309-320 (2004).
4. Rawe J: What will be the 10 hottest jobs? Time 155(21), 72-73 (2000).
5. Moore GA. Crossing the Chasm. HarperCollins Publishers Ltd, London, UK (2002).
6. Mason C: Regenerative medicine: revolution in the making. Med. Device Technol. 16(9), 22 (2005).
7. Viola, J. Lai B, Grad O. The Emergence of Tissue Engineering as a Research Field. National Science Foundation, VA, USA (2003).
8. Levy S. The trend spotter. Wired 13(10) 112-120 (2006).
9. Proposition 71 - The California Stem Cell and Cures Act (2004).
10. Department of Health. UK Stem Cell Initiative: Report and Recommendations. DH Publications, London, UK (2005).
11. Davies A. Development of human embryonic stem cell technology for human therapeutic application. London Regenerative Medicine Network event, London, UK (2006).
12. Mason C. The time has come to engineer tissues and not just tissue engineer. Regenerative Med. 1(3), 303-306 (2006).
13. Deparment of Trade and Industry. Advanced Cell and Tissue Therapies. Global Watch Mission Report. (2006).
14. MacKay G. Analysing the path for the reimbursement of cell therapies in the USA. at 'Commercialisation of tissue engineering & cell therapy' Marcus Evans Conference, London, UK (2006).
15. Eisenbud D. Foundation and growth of a start-up company in the cell-based therapeutic arena. Commercialisation of Tissue Engineering and Cell Therapy, Marcus Evans Conference, London, UK (2006).
16. Bonfiglio GA. Examining Late Stage Venture Capital Funding and Going Public. Commercialisation of tissue engineering & cell therapy, Marcus Evans Conference, London, UK (2006).
17. Yoo J. Examining the migration from concept to clinical success for the first partial reconstruction of a complex internal organ. Commercialisation of tissue engineering & cell therapy, Marcus Evans Conference, London, UK (2006).
18. Caldwell IV WM. Commercialising Human Stem Cell Technology. Commercialisation of tissue engineering and cell therapy. Marcus Evans Conference, London, UK (2006).
19. Lysaght MJ. Tissue engineering: great expectation. London Regenerative Medicine Network event, London, UK (2006).
20. Lysaght MJ. Personal communication (2006).
21. Powers L. Examining Early Stage Funding and Developing Spin-Out Opportunities. Commercialisation of tissue engineering and cell therapy. Marcus Evans Conference. London, UK (2006).
22. Mason C. Hoare M: Regenerative medicine bioprocessing: building a conceptual framework based on early studies. Tissue Eng. (2006) (Epub ahead of print).
23. Mason C, Hoare M: Regenerative medicine bioprocessing- the need to learn from the experience of other fields. Regenerative Medicine 1(5), 615-623 (2006).
24. Hernan CA, Dawson RA, Freedlander E et al.: Clinincal experience using cultured epithelial autografts leads to an alternative methodology for transferring skin cells from the laboratory to the patient. Regenerative Med. 1(6), 809-821 (2006).
25. British Standards Institution. PAS 8: 2006 Guidance on Codes of Practice, Standardised Methods and Regulations for Cell-Based Therapeutics, from Basic Research to Clinical Application. BSI, London, UK (2006).
26. Harris N. Munro C, Patel B: New guidance on codes of practice, standardized methods and regulations, for cell-based therapeutics Regenerative Medicine 1(5), 705-707 (2006)
27. Stephenson EL, Braude PB, Mason, C. Proposal for a universal minimum information convention for the reporting on the derivation of human embryonic stem cell lines, Regenerative Med. 1(6). 739-750 (2006),
28. Greenwood HL, Singer PA, Downey GP. Martin KM, Thorsteinsdottir H. Daar AS: Regenerative medicine and the developing. world. PLoS Med. 3(9), e381 (2006).
29. Williams G. Patentability issues relating to stem cells. London Regenerative Medicine Network event, London, UK (2006).